Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 33Lymphoma 25Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Non-Hodgkin 12Leukemia 9Hodgkin Disease 9Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Multiple Myeloma 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Sarcoma 6Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Triple Negative Breast Neoplasms 5Neutropenia 5Lymphoma, B-Cell, Marginal Zone 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Prostatic Neoplasms 4Osteosarcoma 4Lung Neoplasms 4Waldenstrom Macroglobulinemia 3Testicular Neoplasms 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Neuroblastoma 3Neoplasm Metastasis 3

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Melanoma × pegfilgrastim × Clear all
NCT02650635 2018-09-05

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Mayo Clinic

Phase 1 Terminated
4 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡